NIKKEI 225
38,605.44 -27.58 (-0.07%) HANG SENG
18,068.36 -266.96 (-1.46%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.10 +9.10 (+0.38%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
51,014.65 -678.45 (-1.31%)
REGN Jul 2024 905.000 put
| Previous close | 7.70 |
| Open | 7.70 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 905.00 |
| Expiry date | 2024-07-19 |
| Day's range | 7.70 - 7.70 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksRegeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.
GlobeNewswireUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously published in the Journal of Clinical Oncology Also presented at EHA, a retrospective study of patient outcomes that compared investigational linvoseltamab to real-world standard-of-care treatment in clinical practice TARRYTOWN, N.Y., June 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.
Simply Wall St.Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
